



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

- (15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Description Paragraph(s) 18, 31, 33, 57, 58,
71, 72, 73, 81
Claims DE 1
Claims EN 1, 13
- (51) Int Cl.:
A61K 39/02 ^(2006.01) **A61P 31/02** ^(2006.01)
C12N 1/20 ^(2006.01)
- (86) International application number:
PCT/EP2014/063695
- (87) International publication number:
WO 2014/207202 (31.12.2014 Gazette 2014/53)
- (48) Corrigendum issued on:
14.04.2021 Bulletin 2021/15
- (45) Date of publication and mention
of the grant of the patent:
15.07.2020 Bulletin 2020/29
- (21) Application number: **14734127.5**
- (22) Date of filing: **27.06.2014**

(54) **SWINE DYSENTERY VACCINE**
IMPFSTOFF GEGEN SCHWEINEDYSENTERIE
VACCIN CONTRE LA DYSENTERIE PORCINE

- | | |
|---|---|
| <p>(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR</p> <p>(30) Priority: 28.06.2013 EP 13382255</p> <p>(43) Date of publication of application:
04.05.2016 Bulletin 2016/18</p> <p>(83) Declaration under Rule 32(1) EPC (expert
solution)</p> <p>(73) Proprietors:
• Aquilón Cyl S.L.
24004 León (ES)
• Universidad de León
24071 León (ES)</p> <p>(72) Inventors:
• RUBIO NISTAL, Pedro, Miguel
E-24071 León (ES)
• CARVAJAL UREÑA, Ana, María
E-24071 León (ES)</p> | <p>• GARCÍA DíEZ, Marta
E-24071 León (ES)</p> <p>(74) Representative: Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München (DE)</p> <p>(56) References cited:
WO-A1-95/01805 US-A- 4 100 272</p> <p>• DIEGO R ET AL: "Serpulina hyodysenteriae
challenge of fattening pigs vaccinated with an
adjuvanted bivalent bacterin against swine
dysentery", VACCINE, ELSEVIER LTD, GB, vol.
13, no. 7, 1 January 1995 (1995-01-01), pages
663-667, XP004057591, ISSN: 0264-410X, DOI:
10.1016/0264-410X(94)00018-I</p> |
|---|---|

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- HIDALGO ALVARO ET AL: "Multiple-locus variable-number tandem-repeat analysis of the swine dysentery pathogen, *Brachyspira hyodysenteriae*.", JOURNAL OF CLINICAL MICROBIOLOGY AUG 2010, vol. 48, no. 8, August 2010 (2010-08), pages 2859-2865, XP002716734, ISSN: 1098-660X

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification

Description**Technical field**

- 5 **[0001]** The present invention relates to a composition comprising *Brachyspira hyodysenteriae* bacteria, particularly in the field of immunization against swine dysentery.

Background art

- 10 **[0002]** Swine dysentery (SD), caused by colonic infection with the spirochaete *Brachyspira hyodysenteriae*, remains a major problem worldwide. It affects swine mainly during the fattening period. *Brachyspira hyodysenteriae* is a Gram-negative, oxygen-tolerant, anaerobic spirochete that colonizes the porcine large intestine to cause swine dysentery (SD). This condition is characterized by a severe mucohemorrhagic diarrhoea that primarily affects animals during the growing-finishing period and has been reported from all major pig-rearing countries (Hidalgo, A. et al., Journal of clinical microbiology (2010), 48(8):2859-2865).

- 15 **[0003]** SD is a widely distributed disease around the world, although studies regarding epidemiology are scarce and the reported prevalence significantly varies among them. Thus, *B. hyodysenteriae* reported prevalence ranges from 0 % to near 40 %. Variations in prevalence can be due to the use of different diagnostic methods or to differences among countries in housing, management, feeding regimes, etc. Moreover, whereas in many countries the prevalence may be concealed by the use of antimicrobials as feed additives, in others the ban of antibiotics as growth promoters may have resulted in an increase in SD prevalence (Alvarez-Ordóñez, A. et al., International Journal of Environmental Research and Public Health (2013), 10:1927-1947).

- 20 **[0004]** Carrier pigs play a main role in the epidemiology of swine dysentery and are considered the major source of transmission between herds. *B. hyodysenteriae* survives in the environment for long periods, especially in liquid faeces contained in pits and lagoons, where it may remain infective for up to 60 days. For instance, it can survive during several months in pig faeces at low temperatures. This spirochete also can naturally colonize mice, rheas, chickens, and mallards, and together with mechanical vectors or fomites, this increases the ways in which *B. hyodysenteriae* may be spread within and between herds (Hidalgo, A. et al., Journal of Clinical Microbiology (2010), 48(8):2859-2865).

- 25 **[0005]** The disease causes important direct financial losses, especially in intensive pig farms, derived from a decrease in food conversion efficiency, mortality, lengthening of the fattening period and also indirect losses, like an increase in veterinary expenses, medication, etc. The eradication of the disease through medication is quite difficult, since many clinically recovered animals keep shedding the organism for a long time while acting as carriers.

- 30 **[0006]** Treatment of SD involves the use of antibiotics. Pleuromutilins (tiamulin and valnemulin) have been used for this purpose in the European Union (EU). Tiamulin and valnemulin are semi-synthetic derivatives of the naturally occurring diterpene antibiotic pleuromutilin which show outstanding activity against anaerobic bacteria and are used exclusively in animals, largely in swine. Also macrolides (tylosin and, more recently, tylvalosin) and the closely related lincomycin (lincosamide) have been commonly included in SD therapeutic strategies. However, the emergence of *B. hyodysenteriae* strains with reduced susceptibility to one or more of these antibiotics and the presence of genetically diverse multiresistant isolates has been confirmed in several countries. This fact complicates treatment and control of SD and should alert veterinary surgeons and pig farmers for the need of a strategic approach to select antibiotics, which must only be used on strict indications following proper field and laboratory diagnosis in order to guarantee their long-term efficiency for SD treatment (Alvarez-Ordóñez, A. et al., International Journal of Environmental Research and Public Health (2013), 10:1927-1947).

- 35 **[0007]** The high costs of medication, together with the fact that on many occasions it is impossible to eradicate the infection completely, and the increasing worries about the presence of drug residues in both meat products and the environment, justifies the development of efficient immunoprophylactic methods to control SD (Diego, R. et al., Vaccine (1995), 13(7):663-667).

- 40 **[0008]** Large efforts have been made in order to develop vaccines to control SD since Joens and coauthors (Joens, L.A., et al., American Journal of Veterinary Research (1979), 40:1352-1354) reported that pigs which have recovered from acute SD are protected from disease when subsequently re-exposed to *B. hyodysenteriae*, indicating that the infection can induce a protective immune response (Alvarez-Ordóñez, A. et al., International Journal of Environmental Research and Public Health (2013), 10:1927-1947). However, attempts to develop vaccines to control SD have met with limited success. Hudson (Hudson, M.J. et al., British Veterinary Journal (1974), 130:37-40; Hudson, M.J. et al., Research in Veterinary Science (1976), 21:366-367) developed an attenuated live vaccine which was unable to protect against a subsequent challenge. Glock (Glock, R.D. et al., Proceedings of the 6th International Pig Veterinary Society Congress (1980), Copenhagen, Denmark, p. 521) reported some degree of protection upon challenge after six intravenous injections, at six-day intervals, of an inactivated vaccine. Attenuated or genetically modified live avirulent vaccines may show reduced colonization and cause less immune stimulation (Alvarez-Ordóñez, A. et al., International Journal of

Environmental Research and Public Health (2013), 10:1927-1947).

[0009] An alternative approach is to generate subunit vaccines that might be delivered by the expression of recombinant *B. hyodysenteriae* proteins on a bacterial delivery vector. Efforts have been made to identify *B. hyodysenteriae* proteins for use in subunit vaccines, but vaccination with a recombinant 38 kDa flagellar protein failed to prevent colonization in experimentally infected pigs (Gabe et al., Infection and Immunity (1995), 63:142-148). On the other hand, vaccination with a recombinant 29.7 kDa outer membrane lipoprotein (Bhlp29.7) resulted in partial protection, with fewer animals developing disease than occurred in the control groups. The authors of this study concluded that vaccination also tended to delay the onset of faecal shedding of spirochaetes, but did not necessarily stop it from occurring (La, T. et al., Veterinary Microbiology (2004), 102:97-109). On a study conducted by Holden et al., the efficacy of vaccination with smpB (an outer membrane protein of *B. hyodysenteriae*) was evaluated. However, the response induced after protein vaccination offered only moderate protection against the disease (Holden, J. et al., Veterinary Microbiology (2008), 128:354-363). In most occasions recombinant vaccines tested have failed to provide enough protection in pigs (Alvarez-Ordóñez, A. et al., International Journal of Environmental Research and Public Health (2013), 10:1927-1947).

[0010] Vaccines consisting of whole cell bacterins induce serum antibody responses to *Brachyspira hyodysenteriae*, yet generally fail to protect pigs from disease. The use of *B. hyodysenteriae* bacterins prepared from whole cell lysates may even exacerbate disease upon infection (Waters, W.R. et al., Vaccine (2000), 18:711-719). Moreover, bacterin vaccines tend to be lipopolysaccharide serogroup-specific, which then requires the use of autogenous bacterins. Furthermore, *B. hyodysenteriae* bacterins are relatively difficult and costly to produce on large scale because of the fastidious growth requirements of the anaerobic spirochaete (La, T. et al., Veterinary Microbiology (2004), 102:97-109). In some countries, bacterin vaccines for SD are available commercially, and provide a degree of protection. However, as stated above, they tend to be lipooligosaccharide (LOS) serogroup specific, which then requires the use of autogenous or multivalent preparations (Hampson, D.J. et al., Diseases of Swine (2006), 10th Edition, Blackwell Publishing Professional, Ames, Iowa, U.S.A., pp. 687-688). Other references to SD vaccines in the art can be found in the following patent literature:

US 4748019: The authors found that an effective regime of vaccination comprises administering parenterally to pigs a priming dose of killed virulent or pathogenic *T. hyodysenteriae* effective to stimulate the immune response of the pig (strain "P18A", NCTC 11615) to a subsequent dose of a live avirulent or non-pathogenic strain of *T. hyodysenteriae* (strain "VSI", NCTC 11628) and at about the same time or thereafter administering this live strain orally.

US 5750118: The invention relates to a vaccine against SD comprising an effective quantity of inactivated and adjuvant-containing *T. hyodysenteriae* antigen (virulent or attenuated strain) for intradermal administration. The vaccine antigen is prepared from the strain No. 27164 ATCC, which is inactivated.

US 5281416: The invention relates to a method of vaccination of a pig against SD characterized by parenteral, preferably intramuscular administration to the pig of a live strain or of an oxygen-treated non-viable strain of *T. hyodysenteriae*. Representative strains which may be used are reference virulent strains ATCC 31287, ATCC 31212 and the reference avirulent strain ATCC 27164.

[0011] However, the efficacy of these vaccines was found to be variable. Autogenous preparations (also known as "autovaccines", which may be defined as vaccines prepared from cultures of organisms isolated from the diseased animal's own tissues or secretions) have been used to further improve these vaccines. This approach, albeit efficient, is highly cost and time expensive and confers protection only for a single strain of *B. hyodysenteriae*. Moreover, the vaccination occurs sometime after the strain causing the disease has been identified, which can take several weeks (for instance, under standard procedures, the isolation process from the samples from the farm, initial culture and autovaccine production may take at least 6 weeks). This delay in time often causes the propagation of the bacteria in other animals from the herd, or in extreme circumstances, even to other pig farms. It also provokes serious economic losses and it is itself an expensive procedure to be applied on routine basis. SD thus remains an important endemic infectious disease in many pig rearing countries. There is a huge necessity of an effective and economically affordable vaccine for SD.

Summary of the invention

[0012] Swine Dysentery (SD) is a severe mucohaemorrhagic enteric disease of pigs caused by *Brachyspira hyodysenteriae*, which has a large impact on pig production and causes important losses due to mortality and sub-optimal performance. Considering the emergence of multiresistant strains and the concern that drug residues may be present in meat products or the environment, efficient immunoprophylactic methods to control SD are urgently needed. However, the available vaccines fail to confer a satisfactory degree of protection against infection and, even if they confer a certain degree of protection, they do not provide adequate cross-protective immunity against strains of different serogroups. Moreover, the fabrication and commercialization of autovaccines present many inconveniences. Accordingly, there is a

necessity of vaccines against SD which confer strong protection against strains of different serogroups, namely an effective and universal SD vaccine.

[0013] The inventors have developed a vaccine against SD that, unexpectedly, is as efficient as an autovaccine, despite not having in its composition the strain which causes the infection. This effect is highly surprising, as it is in conflict with the autovaccine theory. This invention provides a vaccine as claimed with efficient and general protection against *Brachyspira hyodysenteriae*, namely a "universal vaccine".

[0014] In a first aspect, the present invention provides a composition as claimed comprising bacteria from at least three genetically diverse strains of *Brachyspira hyodysenteriae*. The composition of the invention may comprise inactivated strains and the genetic diversity may be conferred by selecting the at least three genetically diverse strains of *Brachyspira hyodysenteriae* from different clonal complexes. In a preferred aspect, the genetically diverse strains are at least detected in a proportion of 1 % with respect to the total of detected strains in a region of interest. The region of interest may be any region, preferably Spain.

[0015] In a second aspect, the present invention is related to the composition of the invention for its use as a vaccine, preferably a vaccine against swine dysentery caused by *Brachyspira hyodysenteriae*.

[0016] Moreover, the disclosure provides a method for producing the composition of the invention, comprising selecting at least two genetically different strains and mixing them in equal quantity to achieve a concentration of at least between 10^8 and 10^9 bacteria/mL.

Brief description of the figures

[0017]

Figure 1. Dendrogram of the 44 *B. hyodysenteriae* MLVA types found in the present study and clustered using UPGMA. Roman numerals I to VI indicate clonal complexes defined at the single-locus variant level. The scale bar represents genetic distance as the absolute number of differences in marker alleles among genotypes. Bootstrap values of ≥ 40 % are shown.

Figure 2. MLVA types (circled) and relationships found among them according to the goeBURST algorithm. Solid lines show the single locus variant level, dashed lines show the double-locus variant level, and dotted lines show the triple-locus variant level. Groups at the single-locus variant level are indicated by roman numerals I to VI.

Figure 3. Selection of the strains of the universal vaccine of the examples ("Type 3" (e.g. strain with deposit number CNCM I-4720), "Type 14" (e.g. the strain with deposit number CNCM I-4721) and "Type 20" (e.g. the strain with deposit number CNCM I-4722). The ancestral type strain of the referred clonal complexes (II, V and I) was selected. The selected strains are detected in a proportion of at least 1 % with respect to the total of detected strains in Spain.

Figure 4. Survival curves comparing the groups vaccinated with the autovaccine (dark grey), universal vaccine (black) and non-vaccinated (control, light grey), using the Log Rank test at $\alpha = 0.05$.

Figure 5. Elimination of *B. hyodysenteriae* over the time post-challenge (percentage of positives rectal swabs per week) (black, autovaccine; dark grey, universal vaccine; light grey, non-vaccinated animals (control)).

Figure 6. Incubation period (number of days between the challenge and the appearance of diarrhoea or faecal shedding of the bacteria) in the different groups (black, autovaccine; dark grey, universal vaccine; light grey, non-vaccinated animals (control)).

Figure 7. Percentage of pigs with diarrhoea (a) and bloody diarrhoea (b) after challenge (black, autovaccine; dark grey, universal vaccine; light grey, non-vaccinated animals (control)).

Figure 8. Average daily gain (ADG) on the post-challenge days (black, autovaccine; dark grey, universal vaccine; light grey, non-vaccinated animals (control)).

Figure 9. Daily weight gain (DWG) in the first 9 days after challenge (day 0 to day 9) (black, autovaccine; dark grey, universal vaccine; light grey, non-vaccinated animals (control)).

Figure 10. Measurement of the antibody response (the absorbance at 450 nm directly correlates to amount of antibody produced) of the hiperimmunized rabbits with A, B and C strains against LPS of strain A (CNCM I - 4720) along the experiment (potency assay).

Figure 11. Measurement of the antibody response (the absorbance at 450 nm directly correlates to amount of antibody produced) of the hiperimmunized rabbits with A, B and C strains against LPS of strain B (CNM 1 - 4721) along the experiment (potency assay).

Figure 12. Measurement of the antibody response (the absorbance directly correlates to amount of antibody produced) of the hiperimmunized rabbits with A, B and C strains against LPS of strain C (CNM 1 - 4722) along the experiment (potency assay).

Detailed description of the invention

Composition of the invention

[0018] The present invention relates to a composition as claimed comprising bacteria from at least three genetically diverse strains of *Brachyspira hyodysenteriae*. The term "genetically diverse" as used in the present invention refers to a defined set of genetic, measurable diverse characteristics in the genetic makeup of a species. To determine the diversity of microorganisms in defined environments (ecosystems) or to identify the spread of particular strains between hosts, genetic typing techniques which have the ability to distinguish diverse organisms of the same species are deployed. Importantly, when one is comparing the diversity of a single species between different ecosystems a robust statistical approach that allows an objective assessment is required. To this end, indices of diversity have been defined mathematically that are based on the frequency with which organisms of a particular type occur in a population or can be discriminated by a given typing tool (Grundmann, H. et al., Journal of Clinical Microbiology (2001), 39:4190-4192).

[0019] A relatively high diversity among *B. hyodysenteriae* isolates has been classically described. The ability to understand the epidemiology of SD and to progress to its control depends on the availability of reliable strain typing methods to characterize the isolates. Based on the analysis of semi-purified lipopolysaccharides (LPS), four different serotypes were identified by Baum & Joens (Baum, D.H. et al., Infection and immunity (1979), 25:792-796), although further studies finally differentiated a total of 11 serogroups that included several serotypes (Hampson, D.J. et al., Epidemiology and Infection (1989), 102:75-84; Hampson, D.J. et al., Epidemiology and Infection (1990), 105:79-85; Hampson, D.J. et al., Swine dysentery. In: Intestinal Spirochaetes in Domestic Animals and Humans, pp. 175-209, edited by D. J. Hampson & T. B. Stanton. Wallingford: CAB International, 1997).

[0020] Differences in the geographical distribution of *B. hyodysenteriae* were demonstrated soon after. Reference strains from USA were classified within serotypes 1 and 2 while a higher variability regarding serotype classification was described for isolates from Europe and Australia (Harris et al., Swine Dysentery. In: Straw, B.E., D'Allaire, S.D., Mengeling, W.D. & Taylor, D.J. (Eds.) Disease of Swine. Iowa State University Press (1999), Ames Iowa USA, pp. 579-600). However, there is almost no recent information regarding serotype distribution of *B. hyodysenteriae* isolates. As a consequence of cross reactions, the techniques required to determine the serotype are slow and cumbersome to perform and give inconclusive results in a very high number of the isolates. For that reason, these techniques have been replaced by several molecular methods.

[0021] Different typing tools have been developed to discriminate between *B. hyodysenteriae* field isolates and provide a better understanding of the molecular epidemiology of the pathogen. Among them, a useful tool for strain typing of pathogenic microorganisms that has been introduced during the last few years is the multi-locus variable-number tandem-repeat analysis or MLVA. It has been developed as an important epidemiologic tool for strain typing of pathogenic microorganisms. MLVA is based on the PCR amplification of a number of well-selected and characterized loci that contain short repeat sequences (multiple loci of minisatellites called variable numbers of tandem repeats (VNTRs)). This sort of minisatellite consists of unique direct head-to-tail DNA repeats which can be found in all bacterial genomes and can be used to define specific isolates of bacterial species. In addition, VNTRs have been used to infer the bacterial population structure and phylogeny of diverse bacteria species. Within each repeat sequence locus the number of repeat copies can vary between different strains. By measuring the size of each PCR amplified loci, the number of repeat units can be deduced. Hidalgo and colleagues developed and tested a multiple-locus variable-number tandem-repeat analysis (MLVA) method that could be used in basic veterinary diagnostic microbiology laboratories equipped with PCR technology or in more advanced laboratories with access to capillary electrophoresis. Based on eight loci, and when performed on isolates from different farms in different countries, as well as type and reference strains, the developed MLVA technique was highly discriminatory (Hunter and Gaston discriminatory index, 0.938 [95% confidence interval, 0.9175 to 0.9584]) while retaining a high phylogenetic value. Using the technique, the species was shown to be diverse (44 MLVA types from 172 isolates and strains), although isolates were stable in herds over time. The population structure appeared to be clonal. The finding of *B. hyodysenteriae* MLVA type 3 in piggeries in three European countries, as well as other, related, strains in different countries, suggests that spreading of the pathogen via carrier pigs is likely. MLVA overcomes drawbacks associated with previous typing techniques for *B. hyodysenteriae* and is a powerful method for epidemiologic and population structure studies on this important pathogenic spirochete (Hidalgo, A. et al., Journal of Clinical Microbiology

(2010), 48(8):2859-2865).

[0022] The inventors and their collaborators have applied this method on an international collection of *B. hyodysenteriae* isolates, including 115 Spanish field isolates as well as reference strains and isolates from Australia, Canada, E.E.U.U., UK and The Netherlands.

[0023] MLVA analysis reveals that Spanish field isolates of *B. hyodysenteriae* are heterogeneous and that the population has a clonal structure. A total number of 15 MLVA types were identified among Spanish isolates. Moreover, isolates with the same MLVA type were identified in Spain, UK and The Netherlands. On the other hand, it was concluded that isolates from Australia or EEUU have no common MLVA with Spanish isolates.

[0024] By grouping MLVA types at the single-locus variant level, a total number of six clonal complexes (I to VI) were established (Figure 2).

[0025] The composition of the invention may comprise three, or four, or five, or more genetically diverse strains. The genetic diversity of the strains of the composition of the invention is conferred by selecting the at least three genetically diverse strains of *Brachyspira hyodysenteriae* from different clonal complexes. "Clonal complex" as used in the present invention refers to the several groups established by grouping the MLVA types at the single-locus variant level, as described above. More preferably at least one strain belongs to clonal complex II, and/or at least one strain belongs to clonal complex V, and/or at least one strain belongs to clonal complex I.

[0026] In the composition of the present invention, the genetically diverse strains belong to the ancestral type from the clonal complex.

[0027] The common ancestor within each clonal complex was predicted using the goeBURST algorithm available at <http://goeburst.phyloviz.net/#Software>, a global implementation of the eBURST algorithm. For more details see publications Feil *et al.*, 2004 and Francisco *et al.*, 2009, free at <http://goeburst.phyloviz.net/#Publications>.

[0028] The composition of the present disclosure may further comprise a strain which belongs to a third clonal complex. Preferably, the third clonal complex is selected from the group consisting of clonal complex I, clonal complex II and clonal complex V.

[0029] Accordingly, the composition of the present disclosure comprises at least two, preferably three, genetically diverse strains of *Brachyspira hyodysenteriae*, wherein at least one of the strains belong to clonal complex I, and/or at least one of the strains belong to clonal complex II and/or at least one of the strains belong to clonal complex V.

[0030] The composition of the invention comprises three genetically diverse strains of *Brachyspira hyodysenteriae* wherein one of the strains belong to clonal complex I, one of the strains belong to clonal complex II and one of the strains belong to clonal complex V.

[0031] In the composition of the present invention at least one of the strains is the strain deposited within the *Collection Nationale de Cultures de Microorganismes* (CNCM), Institut Pasteur, on March 14, 2013, with registration number CNCM I-4720, at least one of the strains is the strain deposited on the same date within the CNCM with registration number CNCM I-4721 and at least one of the strains is the strain deposited on the same date within the CNCM with registration number CNCM I-4722.

[0032] Accordingly, the present invention also provides the strains deposited within the *Collection Nationale de Cultures de Microorganismes* (CNCM), Institut Pasteur, on March 14, 2013, with registration numbers CNCM I-4720.

[0033] The strain with registration number CNCM I-4720 belongs to clonal complex II. The strain with registration number CNCM I-4721 belongs to clonal complex V. The strain with registration number CNCM I-4722 belongs to clonal complex I.

[0034] In the composition of the present invention the genetically diverse strains are preferably epidemiologically relevant. In the context of the present invention, "epidemiologically relevant" means that the strains are at least detected in a proportion of 1-100%, preferably at least 1 %, at least 2%, at least 3%, at least 4%, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 50%, at least 75%, at least 90% or 100% with respect to the total of detected strains in a region of interest. Preferably, the genetically diverse strains are at least 1 % detected with respect to the total of detected strains in a region of interest. In the context of the present invention, "detected" means that said strains were identified in the region of interest. The detection of the bacteria *Brachyspira hyodysenteriae* can be done e.g. in rectal swabs, colonic mucosa and/or faecal samples from pigs. For example, the samples can be cultured and the DNA can be extracted following previously reported methods (see e.g. Hidalgo, A. *et al.*, Journal of Clinical Microbiology (2010), 48(8):2859-2865). The presence of *B. hyodysenteriae* can be detected by PCR methods. The presence of *B. hyodysenteriae* can be also confirmed by streaking bacteriology swabs taken from faeces or the colonic walls of pigs onto selective agar plates. After incubation of the plates in an anaerobic environment, the presence of low flat spreading growth of spirochaetes on the plate, and hemolysis around the growth can be recorded (La, T. *et al.*, Veterinary Microbiology (2004), 102:97-109). Alternatively, the presence of *B. hyodysenteriae* can be performed by suspending the samples in PBS and detecting the presence of the bacteria with an indirect immunofluorescence test (IFT) (see e.g. Diego, R. *et al.*, Vaccine (1995), 13(7):663-667). Other methods of detecting the presence of *B. hyodysenteriae* known in the art can be employed.

[0035] The term "region of interest" as employed in the present invention refers to a demarcated area of the Earth,

i.e. to a geographical region or a geographical area wherein the presence of *B. hyodysenteriae* is assessed. There is no specific limitation to the geographical region of interest. It can vary from thousands of kilometers at continental level to a few kilometers at local level. For example, the region of interest can be part of a country, a whole country or more than one country. Preferably, the region of interest is a country or a group of countries. For example, the region of interest can be Europe. Preferably, the region of interest can be Spain, more preferably Iberian Peninsula Spanish territory, in particular Castilla y León, Andalucía and/or Extremadura. Other preferred regions of interest are Italy, The Netherlands, United Kingdom, Australia, Canada and/or United States.

[0036] Moreover, the bacteria comprising the composition of the present invention may be inactivated, i.e. they may be chemically or physically inactivated. The inactivation comprises killing the bacteria with chemicals, heat, and/or radiation. The bacteria of the composition can be inactivated by any inactivation procedure known in the art. Preferably, the bacteria of the composition of the invention are inactivated by treating the bacteria with formaldehyde. Most preferably, the formaldehyde is injected in to the bacteria culture at 0,5% and it is then incubated overnight (18 hours, approx.) at 37 °C with light agitation.

[0037] According to the present invention, the bacteria of the composition, which are preferably inactivated, may be present in a concentration of at least between 10^7 and 10^{12} bacteria/mL, preferably in a concentration of at least 10^7 , or 10^8 , or $5 \cdot 10^8$, or 10^9 , or 10^{10} , or 10^{11} or 10^{12} bacteria/mL, preferably in a concentration of between 10^8 and 10^{10} bacteria/mL, more preferably in a concentration of between 10^8 and 10^9 bacteria/mL, even more preferably in a concentration of $5 \cdot 10^8$ bacteria/mL.

[0038] If the composition comprises bacteria belonging to two strains, they may be present in the composition in a ratio of 1:(0.5-2). If the composition comprises bacteria belonging to three strains, they may be present in the composition in a ratio of 1:(0.5-2):(0.5-2). If the composition comprises bacteria belonging to four strains, they may be present in the composition in a ratio of 1:(0.5-2):(0.5-2):(0.5-2). If the composition comprises bacteria belonging to five strains, they may be present in the composition in a ratio of 1:(0.5-2):(0.5-2):(0.5-2):(0.5-2). Preferably, the composition comprises bacteria in an equal mixture of the selected strains, namely in a ratio of 1:1, 1:1:1, 1:1:1:1, 1:1:1:1:1, depending on how many different strains the composition comprises. In this context, "ratio" means number of bacteria/mL.

[0039] The concentration of bacteria in the composition can be calculated using any method known in the art. For example, Neubauer chamber counting can be used to estimate the number of bacteria present in the composition of the invention.

[0040] The composition of the present invention comprises preferably a total amount of 10^8 to 10^9 inactivated bacteria/mL in an equal mixture of the selected strains, wherein the bacteria belong to three genetically diverse strains of *Brachyspira hyodysenteriae*, wherein one of the strains belong to clonal complex I, one of the strains belong to clonal complex II and one of the strains belong to clonal complex V, and wherein preferably the genetically diverse strains are epidemiologically relevant in a region of interest, i.e. are present in Spain in at least a proportion of 1% with respect to the total of detected strains.

[0041] Preferably, the genetically diverse strains that are epidemiologically relevant in a region of interest are each present in a proportion of at least 9 % with respect to the total of detected strains. Preferably, one of the strains is present in a proportion of at least 13 % with respect to the total of detected strains. More preferably two of the strains are present in a proportion of at least 13 % with respect to the total of detected strains. Most preferably, one of the strains is present in a proportion of at least 24 % with respect to the total of detected strains.

[0042] The composition of the present invention may further comprise an adjuvant. An adjuvant is a component that potentiates the immune response to an antigen and/or modulates it towards the desired immune responses. It may be an inorganic or organic chemical, macromolecule or whole cells of certain killed bacteria which enhances the immune response to given antigen. In the context of the present invention, the adjuvant that may be present in the composition of the invention can be any suitable adjuvant which e.g. enhances, accelerates and prolongs the specific immune response as known in the current art.

[0043] Adjuvants may include for instance:

- Mineral salts, e.g., aluminium hydroxide and aluminium or calcium phosphate gels.
- Oil emulsions and surfactant based formulations, e.g., MF59 (microfluidised detergent stabilised oil-in-water emulsion), QS21 (purified saponin), AS02 [SBAS2] (oil-in-water emulsion + MPL + QS-21), Montanide™ ISA-51, ISA-720, IMS (stabilised water-in-oil emulsion).
- Particulate adjuvants, e.g., virosomes (unilamellar liposomal vehicles incorporating influenza haemagglutinin), AS04 ([SBAS4] AI salt with MPL), ISCOMS (structured complex of saponins and lipids), polylactide co-glycolide (PLG).
- Microbial derivatives (natural and synthetic), e.g., monophosphoryl lipid A (MPL), Detox (MPL + M. Phlei cell wall skeleton), AGP [RC-529] (synthetic acylated monosaccharide), DC_Chol (lipoidal immunostimulators able to self organise into liposomes), OM-174 (lipid A derivative), CpG motifs (synthetic oligonucleotides containing immunostimulatory CpG motifs), modified LT and CT (genetically modified bacterial toxins to provide non-toxic adjuvant effects).

- Endogenous human immunomodulators, e.g., hGM-CSF or hIL-12 (cytokines that can be administered either as protein or plasmid encoded), Immudaptin (C3d tandem array)
- Inert vehicles, such as gold particles towards the desired response to vaccine antigens.

[0044] The most preferred adjuvants are aluminum salts (aluminum hydroxide or aluminum phosphate) and mineral oils. When inoculated they produce a small granuloma that allows the delayed liberation of the antigen (long lasting antigenic stimulation) and the attraction of antigen-presenting cells. This increases the immune response. For example, the adjuvant may be HAVLOGEN™ or Montanide™. Most preferably, the adjuvant may be a commercial oil adjuvant such as Montanide™ IMS 251 C VG (SEPPIC).

[0045] The adjuvant is preferably present in the final composition in a concentration in the final formula of 5 to 50 % vol/vol respect to final injection volume, preferably 5 %, 10 %, 20 %, 25 %, 30 %, 40 %, 50 % or more (vol/vol, i.e. volume with respect to final injection volume). More preferably, the concentration of adjuvant in the final formula is 20 % vol/vol (i.e. volume with respect to final injection volume).

[0046] The composition of the invention may additionally comprise other components. For example, the composition may comprise antiseptic and/or antifungal agents. For example, the composition may further comprise Thimerosal (Sigma), also known as Thiomersal. Preferably, Thimerosal is comprised in an amount of 0.005 to 1 g per 100 ml, preferably in an amount of 0.5, or 0.3 or 0.1, or 0.05, or 0.03, or 0.02, or 0.01 or 0.005 g per 100 ml. More preferably, thimerosal is comprised in an amount of 0.01 g per 100 ml. Further, the composition of the invention may also comprise buffer solutions such as salts. Preferably, the composition of the invention may comprise a buffer in a concentration of 0.01 to 0.5 M, preferably in a concentration of 0.5M, or 0.4M, or 0.3M, or 0.2M, or 0.1M, or 0.05M, or 0.01M. The buffer may be any suitable buffer described in the art. For example, the buffer may be phosphate buffered saline (PBS) or sodium acetate. Preferably, the buffer is sodium acetate 0.1M.

Vaccine of the invention

[0047] The composition of the present invention may be preferably used as a vaccine. A vaccine is a biological preparation that improves immunity to a particular disease. According to the present invention, the vaccine is a vaccine against swine dysentery (SD). Swine dysentery is caused by *Brachyspira hyodysenteriae*.

[0048] The composition of the invention for use as a vaccine (from now on, the vaccine of the invention) may be suitable for administration to swine in a particular geographical region of interest. As described above, the region of interest is not particularly limited, and may comprise one or more countries. For example, the region of interest can be Europe. Preferably, the region of interest can be Spain, more preferably Iberian Peninsula Spanish territory, in particular Castilla y León, Andalucía and/or Extremadura. Other preferred regions of interest are Italy, The Netherlands, United Kingdom, Australia, Canada and/or United States.

[0049] The vaccine of the invention may be administered before the infection, and/or shortly after it. For example, the vaccine of the invention may be administered 1 to 20 days after the outbreak of the disease, preferably 1, or 2, or 3, or 4, or 5, or 6, or 7, or 8, or 9, or 10, or 15, or 20 days after the outbreak of the infection. The vaccine may also be administered 1-4 weeks after the outbreak of the disease, preferably 1, 2, 3 or 4 weeks after the outbreak of the infection.

[0050] The vaccine of the invention may be administered by parenteral administration and/or oral administration. Preferably, the vaccine of the invention is administered by parenteral administration, more preferably by subcutaneous and/or intramuscular and/or intradermal administration, and even more preferably by intramuscular administration. For example, the vaccine of the invention may be injected intramuscularly into the neck muscles of swine.

[0051] The administered dosage of the vaccine of the invention may range from 1 mL to 5 mL. For example, one dosage of the vaccine of the invention may be 1 mL. For example, one dosage of the vaccine of the invention may be 2 mL.

[0052] The administered dosage of the vaccine of the invention may comprise between 10^7 and 10^{12} bacteria/dose, preferably between 10^8 and 10^{10} bacteria/dose, more preferably 10^9 bacteria/dose. The administered dosage of the vaccine of the invention may comprise between 10^8 and 10^9 bacteria/mL. The administered dosage of the vaccine of the invention may comprise 10^9 bacteria/mL. The administered dosage of the vaccine of the invention may comprise $5 \cdot 10^8$ bacteria/mL in 2 mL/dose.

[0053] Accordingly, the preferred total number of bacteria per dose which may be administrated to swine is 10^9 bacteria.

[0054] The vaccine of the present invention is preferably an injectable vaccine.

Vaccination protocol

[0055] According to the present invention, the vaccine of the invention may be preferably administered to the swine after weaning, most preferably two weeks after weaning. For example, the swine may be vaccinated since the fourth week of life. According to the present invention, the swine may be vaccinated twice (revaccinated). The swine are preferably revaccinated two weeks after the first vaccination. For example, the swine may be vaccinated two weeks

after weaning, e.g. at the age of four weeks. Then, the second vaccine (revaccination) may take place at the age of six weeks (i.e. two weeks after the first vaccine was administered). For example, the swine may be vaccinated two weeks after weaning, e.g. at the age of five weeks. Then, the second vaccine (revaccination) may take place at the age of seven weeks. For example, the swine may be vaccinated two weeks after weaning, e.g. at the age of six weeks. Then, the second vaccine (revaccination) may take place at the age of eight weeks. Vaccination for the first time at the age of four weeks is preferred.

[0056] Weaning can occur at 21 days of age (La, T. et al., Veterinary Microbiology (2004), 102:97-109). Weaning can also occur at 15 days of age, or at any other age, depending on the heard.

[0057] Thus, the present disclosure provides the following items:

1. A composition comprising bacteria from at least two genetically diverse strains of *Brachyspira hyodysenteriae*.
2. The composition according to item 1, wherein the bacteria are inactivated.
3. The composition according to items 1 and/or 2, wherein the bacteria are present in a concentration of at least between 10^8 and 10^9 of total bacteria/mL.
4. The composition according to one or more of the preceding items, wherein the genetic diversity is conferred by selecting the at least two genetically diverse strains of *Brachyspira hyodysenteriae* from different clonal complexes.
5. The composition according to one or more of the preceding items, wherein at least one strain belongs to clonal complex II.
6. The composition according to one or more of the preceding items, wherein at least one strain belongs to clonal complex V.
7. The composition according to one or more of the preceding items, wherein at least one strain belongs to clonal complex I.
8. The composition according to one or more of the preceding items, wherein the genetically diverse strains are detected in a proportion of at least 1 % in a region of interest with respect to the total of detected strains.
9. The composition according to item 8, wherein the region of interest is Spain.
10. The composition according to one or more of the preceding items, wherein the genetically diverse strains belong to the ancestral type from each clonal complex.
11. The composition according to one or more of the preceding items, wherein the composition further comprises a strain which belongs to a third clonal complex.
12. The composition according to item 11 wherein the third clonal complex is selected from the group comprising clonal complex I, clonal complex II and clonal complex V.
13. The composition according to one or more of the preceding items, wherein at least one of the strains belong to clonal complex I, at least one of the strains belong to clonal complex II and/or at least one of the strains belong to clonal complex V.
14. The composition according to item 13 wherein at least one of the strains is the strain with deposit number CNCM I-4720, at least one of the strains is the strain with deposit number CNCM I-4721 and/or at least one of the strains is the strain with deposit number CNCM I-4722.
15. The composition according to one or more of the preceding items further comprising an adjuvant.
16. The composition according to item 15, wherein the adjuvant is selected from the group consisting of aluminum salts (preferably aluminum hydroxide and/or aluminum phosphate) and mineral oils.
17. The composition according to item 16, wherein the adjuvant is an oil adjuvant, preferably Montanide™ 251 C VG.

18. A composition according to one or more of the preceding items for use as a vaccine.

19. The composition according to item 18, wherein the vaccine is a vaccine against swine dysentery.

20. The composition according to item 19, wherein the swine dysentery is caused by *Brachyspira hyodysenteriae*.

21. The composition according to one or more of items 18 to 20, wherein the vaccine is suitable for administration to swine in a region of interest.

22. The composition according to item 21, wherein the region of interest is Spain.

23. The composition according to one or more of items 18 to 22, wherein the genetically diverse strains are detected in a proportion of at least 1 % with respect to the total of detected strains in a region of interest.

24. The composition according to one or more of items 18 to 23, wherein the vaccine is administered by parenteral administration.

25. The composition according to item 24, wherein the vaccine is administered by intramuscular administration.

26. The composition according to one or more of items 18 to 25, wherein the swine are vaccinated two weeks after weaning.

27. The composition according to item 26, wherein the swine are revaccinated two weeks after the first vaccination.

28. A method for producing a composition according to one or more of items 1 to 27, comprising selecting at least two genetically different strains and mixing them in equal quantity to achieve a concentration of at least between 10^8 and 10^9 of total bacteria/mL.

29. The method according to item 28, wherein the at least two genetically different strains are also epidemiologically relevant.

30. The method according to one or more of items 28 to 29, further comprising the inactivation of the bacteria.

31. The method according to one or more of items 28 to 30 wherein the genetic diversity is conferred by selecting each strain from different clonal complexes.

32. The method according to one or more of items 29 to 31, wherein the epidemiologic relevance is conferred by selecting strains that are detected in a proportion of at least 1 % with respect to the total of detected strains in a region of interest.

33. The method according to item 32, wherein the region of interest is Spain.

Examples

Example 1. Multiple-Locus Variable-Number Tandem-Repeat Analysis of *Brachyspira hyodysenteriae*

MVLA analysis

[0058] A set of 172 porcine *B. hyodysenteriae* isolates and strains was used in this study, including the three reference strains B204^R (ATCC 31212), B234^R (ATCC 31287) and WA1^R (ATCC 49526) and the type strain B78^T (ATCC 27164).

[0059] Duplicates of the B204^R and B78^T strains were obtained from the bacterial collections held at the University of León and Murdoch University. The strains and field isolates were from Spain (n = 115), Australia (n = 36), Canada (n = 3), the United States (n = 7), the United Kingdom (n = 4), and Netherlands (n = 7) and had been recovered from the 1970s to 2009. Twenty-three isolates were recovered from Iberian pigs, a local Spanish breed. These pigs contribute to the preservation of the "dehesa," a specific Mediterranean ecosystem located in the western regions of the country (Castilla y León, Extremadura, and Andalucía), where they are traditionally reared in extensive units. The field isolates were recovered from different herds, except for 26 Spanish isolates that were additionally isolated from 11 herds on different sampling occasions. *B. hyodysenteriae* isolates from the University of León and Murdoch University bacterial

collections were identified and cultured, and DNA was extracted in each supplying laboratory by previously reported methods. Working dilutions of extracted DNA were prepared by adjusting them to 1 to 20 ng/μL using a NanoDrop 1000 UV-Vis spectrophotometer (Thermo Scientific, Wilmington, DE).

Identification of tandem repeats and primer design

[0060] The chromosomal DNA sequence of *B. hyodysenteriae* WA1^R was retrieved from GenBank (accession no. NC_012225) and investigated for potential tandem repeats using the default parameters of the Tandem Repeat Finder program, available as a Web service (<http://tandem.bu.edu/>). The selected tandem-repeat loci were ranked by consensus length, and those with lengths between 25 and 300 bp were used to design primers within the flanking regions. Loci were named Bhyo, followed by the repeat length ranking number (from 1 to 23), separated by an underscore.

Tandem-repeat screening and MLVA setup

[0061] In a preliminary step, DNA extracted from *B. hyodysenteriae* strain B204^R was used to estimate the empirical annealing temperature of the 23 selected primer pairs in a gradient PCR. The PCR was run in a Mastercycler Gradient (Eppendorf Scientific Inc., Westbury, NY) with an initial step of 95 °C for 5 min, followed by 30 cycles of a three-step cycle protocol consisting of 94 °C for 30 s, 56 ± 8 °C for 30 s, and 72 °C for 1 min and a final extension step of 72 °C for 10 min. To screen the usefulness of the 23 selected loci as epidemiological markers, DNA samples of *B. hyodysenteriae* strains B204^R and B78^T and isolates 3, 19, 23, 53, 64, H9, and H72, which have been shown to have genetic differences by PFGE and RAPD in a previous investigation (Hidalgo, Á. et al., Epidemiology & Infection (2010), 138:76-85), were used. In addition, tandem-repeat data generated for *B. hyodysenteriae* strain WA1^R were taken into account. Each locus was amplified individually, and the length of the product was analyzed by conventional agarose gel electrophoresis using a 100-bp DNA ladder (Invitrogen, Carlsbad, CA). Loci were selected according to their length polymorphism and their ability to generate amplicons for most of the DNA samples tested. To confirm the length of the PCR product, as well as the number of repeats, the consensus patterns, and the sizes of the flanking regions, amplicons were purified using the AxyPrep PCR Cleanup kit (Axygen Biosciences, Union City, CA) and sequenced by using fluorescently labeled dideoxynucleotide technology according to the manufacturer's recommendations (Applied Biosystems, Foster City, CA). On this basis, eight VNTR loci were selected to be used in the final typing tool.

PCR amplifications for MLVA

[0062] The isolates obtained with the bacterial collection selected for this study were analyzed by independently amplifying the eight selected VNTR loci in a Mastercycler apparatus (Eppendorf). The primers for PCR and thermocycling conditions used are described in Table 1. PCR mixtures were prepared using 0.2-mL sterile tubes containing 1x PCR buffer (20 mM Tris HCl [pH 8.4], 50 mM KCl), 5 mM MgCl₂, 1 U of Platinum Taq DNA polymerase (Invitrogen), 200 μM deoxynucleoside triphosphate mix (Invitrogen), 0.2 μM each forward and reverse primers, 2 μL of the DNA working dilution, and sterile distilled water up to a final volume of 50 μL. PCR products were resolved in agarose gels, and their allelic sizes were estimated using a 100-bp DNA ladder (Invitrogen). Amplicons of alleles not detected in the setup step were sequenced as described above. In addition, in order to ensure the repeatability of the technique, 28 DNA samples were randomly selected and tested again. Reproducibility between laboratories was assessed by independent determination of the VNTR types of 14 isolates at the University of León and Murdoch University.

Table 1: Primers for PCR and thermocycling conditions

Primer	Sequence	Thermocycling program
Bhyo_6	SEQ ID NO. 1: F, AAATATAACTCATATTCATAACAAG SEQ ID NO. 2: R, AGAGAACTTCAAAAACTTC	30 x (94°C for 20 s, 52 °C for 20 s, 72°C for 30 s), 72°C for 5 min
Bhyo_7	SEQ ID NO. 3: F, AGTAATAAATTTAAAAATCTCTAGGGTGG SEQ ID NO. 4: R, GGTTTGGTAGAACAATCTGC	30 x (94°C for 20 s, 59.5°C for 20s, 72°C for 30 s), 72°C for 5 min
Bhyo_12	SEQ ID NO. 5: F, CGTATGATTATTTACTTGTCAG SEQ ID NO. 6: R, TTTTATTACAGCAACTTTACTC	30 x (94°C for 30 s, 59°C for 30 s, 74°C for 40 s)
Bhyo_17	SEQ ID NO. 7: F, TTTTGGCCATAAATATCTCTC SEQ ID NO. 8: R, GAAATGCCGTCCTTCTTAG	30 x (94°C for 30 s, 59°C for 30 s, 74°C for 40 s)

(continued)

Primer	Sequence	Thermocycling program
Bhyo_21	SEQ ID NO. 9: F, AAAATAATGATGAAGTATCTAATG SEQ ID NO. 10: R, AAGTATCAGGTAAAGGTAAATC	30 x (94°C for 20 s, 52°C for 20 s, 72°C for 30 s), 72°C for 5 min
Bhyo_22	SEQ ID NO. 11: F, AGATTAATAACTGACGGAG SEQ ID NO. 12: R, AGCACAAGAACCTTCAAAAC	30 x (94°C for 30 s, 55°C for 30 s, 72°C for 60 s), 72°C for 5 min
Bhyo_10	SEQ ID NO. 13: F, CTCTCTTTTATATTTTATTATAGTTG SEQ ID NO. 14: R, TTGATGAAATTAGACCATTC	30 x (94°C for 30 s, 55°C for 30 s, 72°C for 40 s), 72°C for 5 min
Bhyo_23	SEQ ID NO. 15: F, CACCCTTTAGACTTATTATTTTATTTTG SEQ ID NO. 16: R, TTGTTCTGCGTGCGTGTAG	30 x (94°C for 30 s, 55°C for 30 s, 72°C for 40 s), 72°C for 5 min

[0063] The eight primer pairs used in the individual PCRs were grouped into two sets (set 1 and set 2); labeled fluorescently with 6-carboxyfluorescein (6-FAM™), VIC®, PET®, or NED™ (Applied Biosystems) at the 5'- end of the forward primers; and pooled prior to performing a multiplex PCR using the Qiagen Multiplex PCR kit according to the manufacturer's recommendations (Qiagen, Germantown, MD).

Tables 2 and 3: Primer sets

Primer set 1		
Primer	Fluorescence	Final concentration
Bhyo_7	6-FAM™	0,25 µM
Bhyo_12	VIC®	0,25 µM
Bhyo_17	NED™	0,15 µM
Bhyo_22	PET®	0,15 µM
Primer set 2		
Primer	Fluorescence	Final concentration
Bhyo_6	6-FAM™	0,25 µM
Bhyo_10	PET®	0,25 µM
Bhyo_21	VIC®	0,15 µM
Bhyo_23	NED™	0,15 µM

[0064] A 25 µl volume was used for multiplex PCR amplification with a thermal cycling protocol of 95 °C for 15 min; 30 three-step cycles of 94 °C for 30 s, 55/53°C (set 1/set 2) for 90 s, and 72 °C for 90 s; and a final extension step of 72 °C for 10 min. Multiplex PCR products were diluted 1:10 in distilled water before 1 µl of this dilution was mixed with 0.5 µl of 1200 LIZ Size Standard (Applied Biosystems) and 10.5 µl of formamide. After the mixture was heated for 3 min at 96 °C and rapidly cooled on ice, GeneScan analysis was performed using an ABI 3730 DNA analyzer (Applied Biosystems). The freely available program Peak Scanner Software v 1.0 (Applied Biosystems) was used to size the PCR fragments for each locus.

Data analysis

[0065] The number of repeats was calculated according to the following formula:

$$\text{Number of repeats} = [\text{Fragment size (bp)} \times \text{Flanking regions (bp)}] / \text{Repeat size (bp)}.$$

[0066] The results were approximated to the nearest lower integer and sequentially scored (Bhyo_6, Bhyo_7, Bhyo_12, Bhyo_17, Bhyo_21, Bhyo_22, Bhyo_10, and Bhyo_23) to create a numerical profile that defined each strain. When PCR amplification was undetectable, the assigned number of repeats was 99. MLVA profiles were ascribed to MLVA types

by assigning a whole number. Isolates were considered genetically identical when the numerical profiles for all eight loci matched. The Hunter-Gaston diversity index was used to measure the polymorphism of individual loci and the index of discrimination of the MLVA typing method for the eight combined VNTR loci (Hunter, P. R. and M. A. Gaston, Journal of Clinical Microbiology (1988), 26:2465-2466). Approximate 95% confidence intervals (CI) were calculated as described by Grundmann et al. (Journal of Clinical Microbiology (2001), 39:4190-4192). Redundant isolates (n = 26) were removed prior to calculating the previous indexes. The Sequence Type Analysis and Recombinational Tests (START2) program, available for free at <http://pubmlst.org/software/analysis/start2/>, was used to analyze the MLVA profiles and types of the spirochetes tested. A phylogenetic tree of the MLVA types was constructed based on the unweighted-pair group method using average linkages (UPGMA) clustering strategy. A bootstrap analysis for 1,000 replicates was undertaken using FreeTree at <http://web.natur.cuni.cz/flegr/programs/freetree.htm>. The goeBURST algorithm, available at <http://goeburst.phyloviz.net/#Software>, a global implementation of the eBURST algorithm (Feil, E. J. et al., Journal of Bacteriology (2004), 186:1518-1530.), was used to identify groups of related genotypes of *B. hyodysenteriae* at single-, double-, and triple-locus variant levels. Population structure was tested as proposed by Smith et al. (Proceedings of the National Academy of Sciences U. S. A. (1993), 90:4384-4388), taking into account the modifications proposed by Haubold et al. (Genetics (1998), 150:1341-1348.) for the calculation of the critical value (LMC) of the distribution of the variance of the pairwise differences (VD), and expressed as a standardized index of association (ISA).

Results

Identification of VNTR markers

[0067] Investigation of the chromosomal sequence of *B. hyodysenteriae* WA1^R with the Tandem Repeat Finder program identified 404 repeats in tandem through the whole chromosome, with 135 repeats/Mbp. Subsequent selection of the most suitable tandem-repeat markers decreased the number to be included in the MLVA to 23, which were consecutively named Bhyo_1 to Bhyo_23 and used to design primers within the flanking regions. Fifteen loci that were monomorphic or failed to amplify all or most of the nine selected isolates with the specific primers were discarded. The remaining eight loci were polymorphic, with different allele sizes. Sequencing of the PCR products confirmed that the length polymorphism was due to differences in the copy number of tandem repeats and that the consensus pattern, its period size, and the flanking regions were stable (Table 4). Therefore, eight loci (Bhyo_6, Bhyo_7, Bhyo_12, Bhyo_17, Bhyo_21, Bhyo_22, Bhyo_10, and Bhyo_23) were included in the MLVA scheme for *B. hyodysenteriae*. These loci were distributed from position 1236667 to position 2949421 of the WA1^R genome (Table 4). Four loci, Bhyo_6, Bhyo_10, Bhyo_21, and Bhyo_22, were placed in open reading frames encoding hypothetical proteins, while the other four were located in intergenic regions. Bhyo_7 was placed between the genes for methyl-accepting chemotaxis protein McpA and a hypothetical protein. Bhyo_12 was between the genes for a putative glycosyltransferase family 2 protein and a hypothetical protein. Bhyo_17 was between the genes for glycerol 3-phosphate dehydrogenase and ferredoxin. Bhyo_23 was between the genes for a hypothetical protein and putative RarR, predicted to be a permease

Table 4: Features of the loci included in the MLVA

Locus	Size (bp) of repeat	Flanking region	Position
Bhyo_6	156	78	1236667-1237672
Bhyo_7	135	177	1818959-1819765
Bhyo_10	111	88	1754196-1755095
Bhyo_12	105	59	2949083-2949421
Bhyo_17	76	175	1690628-1691034
Bhyo_21	33	195	1396843-1397034
Bhyo_22	30	153	2597474-2597543
Bhyo_23	26	102	1838685-1838736

MLVA typing

[0068] The set of eight VNTR markers was used to type the full collection of 174 *B. hyodysenteriae* strains and isolates recovered from pigs in several countries (including the duplicates of B78^T and B204^R). The strains and isolates were efficiently amplified, and the lengths of the PCR products were converted into numbers of repeats. Sequencing of new

alleles that were identified at this stage confirmed that the length differences represented variations in the number of the previously detected repeat motifs. The marker Bhyo_10 was the most diverse VNTR, with eight different numbers of repeats (99, 2, 3, 5, 6, 7, 8, and 10), with an assigned number of repeats of 99 because of a lack of amplification. Seven numbers of repeats were detected for locus Bhyo_17, while markers Bhyo_6, Bhyo_7, and Bhyo_21 each presented six numbers of repeats. Loci Bhyo_12 and Bhyo_22 showed a discontinuous distribution of four numbers of repeats. VNTR marker Bhyo_23 showed less diversity, with only two different numbers of repeats, 1 and 2, detected. An accurate estimation of the degree of polymorphism of the loci was achieved by means of the Hunter-Gaston diversity index, with the discrimination powers of the loci ranging from 0.141 to 0.764. Locus Bhyo_10 was the most discriminatory, with a value of 0.764, followed by loci Bhyo_7, Bhyo_6, Bhyo_17, and Bhyo_21, with values of 0.761, 0.718, 0.71, and 0.699, respectively. Loci Bhyo_12 and Bhyo_23 had diversity indexes of 0.472 and 0.318, respectively, while the most conserved locus was Bhyo_22, with a polymorphism index of 0.141.

[0069] The Hunter-Gaston discriminatory index of the MLVA typing method at eight loci for 146 strains and isolates from different herds was 0.938 (95% CI, 0.9175 to 0.9584). Analysis of the combination of the eight VNTR loci for all of the *B. hyodysenteriae* isolates and strains showed 44 MLVA types, which differed by at least one repeat for one of the eight loci among two different types. The MLVA types of the reference strains were type 35 for WA1^R, type 23 for B204^R, and type 10 for B234^R, while the type strain B78^T was assigned to MLVA type 28. Analysis of the different MLVA types in each country showed the existence of considerable diversity. There were 15 types (1, 2, 3, 5, 9, 11, 12, 13, 14, 18, 19, 20, 22, 24, and 37) found among the 89 Spanish isolates from different herds, 16 types (15, 16, 17, 25, 26, 31, 32, 33, 34, 35, 36, 38, 39, 42, 43, and 44) among the 36 Australian isolates, 2 types (21 and 27) for the three Canadian isolates, 3 types (3, 6 and 41) for the seven from Netherlands, 4 types (3, 8, 29, and 30) for the four strains from the United Kingdom, and 6 types (4, 7, 10, 23, 28, and 40) for the seven isolates and strains from the United States. MLVA type 3 was shared by isolates from Spain, the United Kingdom, and Netherlands. The MLVA types were stable for the herds where more than one isolate was recovered on different sampling occasions. *B. hyodysenteriae* strain WA1^R showed a mismatch for locus Bhyo_6 between the length of the PCR product, 780 bp (four numbers of repeats), and the data derived from the sequenced genome, 1,092 bp (six numbers of repeats). Isolates and strains included in the repeatability and reproducibility tests had the same MLVA types at the different testing times. Moreover, each of the duplicates of the *B. hyodysenteriae* type and reference strains, B78^T and B204^R, from the University of León and Murdoch University collections, generated the same MLVA patterns.

MLVA types and bacterial population analysis

[0070] An evolutionary tree based on MLVA profiles and constructed according to the UPGMA clustering strategy for the 44 MLVA types of *B. hyodysenteriae* determined in this study is shown in Fig. 1. MLVA type relationships at the single-, double-, and triplelocus variant levels depicted with the goeBURST algorithm are shown in Fig. 2. Six clonal complexes (I to VI) were established at the single-locus variant level. Three new groups appeared when investigating double-locus variants, while three single locus variant groups (II, III, and IV) were clustered together at this level. When high-level edges were displayed to study relationships at the triple-locus variant level, a large cluster appeared which included groups I to IV, and group V was expanded by two more types. MLVA types 4, 5, 10, and 15 were not linked with any of the other types detected at any of the levels studied. Population linkage disequilibrium was detected for the 146 isolates from different herds ($I^S_A = 0.1359$; $P < 0.001$) and for the different MLVA types ($I^S_A = 0.0336$; $P = 0.005$).

Example 2: Selection and culture of the universal vaccine strains

[0071] Three *Brachyspira hyodysenteriae* strains were selected, each of which belongs to different clonal complexes (clonal complexes I, II and V). Each genetically diverse selected strain belongs to the ancestral type from each clonal complex. Moreover, each selected strain is at least 1 % detected with respect to the total of detected strains in Spain (Figure 3). The strains are the ones deposited within the *Collection Nationale de Cultures de Microorganismes* (CNCM), Institut Pasteur, on March 14, 2013, with registration numbers CNCM I-4720, CNCM I-4721 and CNCM I-4722.

[0072] The strain with registration number CNCM I-4720 belongs to clonal complex II. The strain with registration number CNCM I-4721 belongs to clonal complex V. The strain with registration number CNCM I-4722 belongs to clonal complex I.

[0073] CNCM I-4720 is 24,7 % detected with respect to the total of detected strains in Iberian Peninsula Spanish territory. CNCM I-4721 is 13,5 % detected with respect to the total of detected strains in Iberian Peninsula Spanish territory. CNCM I-4722 is 9 % detected with respect to the total of detected strains in Iberian Peninsula Spanish territory.

[0074] The isolated bacteria (free from contaminants) are inoculated in agar-blood plates. The plates are kept in anaerobic conditions at 39,5 °C for 4-5 days, until hemolysis in the whole plate is observed. Agar fragments at the hemolysis borders and they are inoculated in a new agar-blood plate, incubated in the same conditions. Bacteria are passed to a new agar-blood plate and, in parallel, to a Fastidious Anaerobe Agar (FAA) plate, and bacteria are cultured

in the same conditions during 3-4 days. The bacteria can then be transferred to liquid growth medium, and cultured.

[0075] For fermentation, bacteria are incubated in approx. 4 L of suitable culture medium (such as Brain Heart Infusion media from Merck) at 38,5 °C with light agitation (50 rpm) in an oxygen-free atmosphere. The fermentation occurs until the optical density is approx. 1.6 (or until there are around 10^9 UFC/mL (usually between 15 and 30 hours)).

Example 3: Inactivation of the bacteria

[0076] After fermentation, 4 L (approx.) of culture are pumped into a sterile flask and centrifuged (2 X 7000 rpm, 10 minutes). Resulting pellets are suspended in 1 L sodium acetate buffer 0.1 M. The inactivation of the culture is carried out with an injection of formaldehyde at 0.5 % and incubation during 24 hours at 37 °C with light agitation (50 rpm). Next day the suspension is centrifuged and resuspended in sterile sodium acetate 0.1 M. The antigen (10^9 - 10^{10} bacteria/mL, approx.) is kept at 4 °C until mixing with adjuvant and excipients for vaccine manufacturing.

Example 4: Vaccine formula (universal vaccine of the invention)

[0077] The vaccine comprises the following components. The term antigen refers to the above-mentioned selected *Brachyspira hyodysenteriae* strains, and the final concentration of antigen is 10^9 bacteria/mL in an equal mixture of the three selected strains.

Component	Quantity (for 2 L of vaccine)	Percentage/final concentration in the vaccine
Antigen	200 mL	10^9 bacteria/mL
Montanide IMS 251 C VG (Seppic)	400 mL	20%
Thimerosal 5% (Sigma)	4 mL	0.01%
Sodium acetate 0,1 M (Boente)	1400 mL	

[0078] The components were mixed by agitation at 4 °C overnight.

Example 5: Comparison between an efficient autovaccine and the universal vaccine of the invention

[0079] The following conditions were used:

1.-The pigs used in this example came from a farm free of spirochaetal infections and with low health status, due to the difficulty to achieve a good challenge in pigs with high health status.

2.-The diet was manipulated in order to induce a very high dysbiosis in the intestine. The importance of diet in swine dysentery is also well known. In this experiment the feed was mixed with a 50% of soy flour that had 46 % of protein. Pigs received this diet from the day of the challenge on (10 days in total).

3.-The strain used for the challenge was the reference strain B204 (ATCC Number: 31212). The strain was previously passed three times in pigs to fully maintain its pathogenicity and to verify that the experimental infection would be appropriate. This ensures that the strain used has a high pathogenicity and causes a severe disease in infected pigs.

[0080] The following three groups of six pigs each were used:

- Group 1 (autovaccine): piglets were vaccinated via intramuscular (i.m.) with the autovaccine (inactivated B204 and adjuvant, same protocol as above but with inactivated B204 as antigen) at 6 weeks of life and revaccinated at 8 weeks of life. Each dose contained 10^9 bacteria.
- Group 2 (universal vaccine): piglets were vaccinated via i.m. with the universal vaccine (the polyvalent inactivated and adjuvanted vaccine, comprising the three selected field strains). The vaccination protocol was the same as above (piglets were vaccinated at 6 weeks of life and revaccinated at 8 weeks). The dose was also 10^9 bacteria in an equal mixture of the three selected strains.

- Group 3 (control group, unvaccinated): the same adjuvant (without bacterial antigen) was injected i.m. to piglets at 6 and 8 weeks of life (same protocol as above).

[0081] Vaccination and revaccination were performed in the farm. The piglets were kept on the farm until the 10th week of age and were then moved to the experimental facilities of the University of León. Piglets belonging to the three experimental groups were mixed among them in these facilities.

[0082] The experimental infection was made 3 weeks after the second dose, when piglets were 11 weeks old. Every pig of each group received 100 mL of a fresh culture of B204 type strain containing 10⁹ bacteria/mL orally during 3 consecutive days. The diet was modified at first day of challenge, as mentioned above.

[0083] Since the first day of challenge (PID 1) pigs were daily sampled by collecting rectal swabs and faecal shedding of *B. hyodysenteriae* was monitored by microbiological culture. From PID 1 on, general health status and presence or diarrhoea and characteristics of the faeces were also recorded.

Results:

[0084]

1.-Mortality

	MORTALITY		
	Dead pigs (total)	%	PID (post-infection days)
Group 1 (Universal vaccine)	1(6)	14.2	29
Group 2 (Autovaccine)	1(6)	14.2	29
Group 3 (Control)	3(6)	50	7, 9, 13

[0085] In the group of pigs vaccinated with the universal vaccine, one piglet died in the 17th day after experimental infection. In this case, death was caused by pneumonia. The death pig had not eliminated *Brachyspira hyodysenteriae* in faeces before its death.

[0086] Mortality caused by swine dysentery was the same in the group of pigs vaccinated with the universal vaccine and those vaccinated with the autovaccine (1 pig in each group) and three times lower than in the unvaccinated pigs of the control group (3 pigs died).

[0087] Given the Odds ratio, mortality risk was 6 times higher in those animals from the control group as compared with those vaccinated with the universal vaccine or with the autovaccine (OR = 6; CI 95 % 0,28-246,02).

[0088] In both groups of vaccinated pigs (those vaccinated with the universal vaccine and those vaccinated with the autovaccine) the death of the pig occurred at day 29 post-challenge, whereas in the control group the three pigs died on days 7, 9 and 13 post-challenge (Figure 4).

[0089] As expected, no difference was observed between survival curves of vaccinated with the universal vaccine and autovaccinated animals ($p = 0.9372$).

2. -Incubation period

	INCUBATION PERIOD				
	Mean (days)	Standard deviation	Minimum (days)	Maximum (days)	Mode (days)
Group 1 (Universal vaccine)	5.8	2.28	3	8	8
Group 2 (Autovaccine)	7.6	2.07	4	9	8
Group 3 (Control)	4	2.283	1	6	6

[0090] The incubation period, defined as the number of days between the challenge and the appearance of diarrhoea or faecal shedding of the bacteria was significantly longer in those pigs from the control group as compared with auto-vaccinated animals ($F = 7.36$; $p = 0.024$). This incubation period was also higher for vaccinated pigs as compared with controls. No statistically significant differences were found between both groups of vaccinated and autovaccinated pigs ($F = 1.7$; $p = 0.228$) (Figure 6).

3.-Diarrhoea and bloody diarrhoea

	DIARRHOEA		
	Days sampled	Days with diarrhoea Total days (%)	Days with bloody diarrhoea Total days (%)
Group 1 (Universal vaccine)	167	58 (34.73)	20 (11.97)
Group 2 (Autovaccine)	160	63 (39,35)	11 (6.85)
Group 3 (Control)	122	64 (52.46)	35 (28.69)

[0091] The proportion of days with diarrhoea was significantly higher in the control group as compared with vaccinated pigs with the universal vaccine ($\text{Chi}^2 = 8.37$; $p = 0.004$) and with autovaccinated pigs ($\text{Chi}^2 = 4.27$; $p = 0.038$).

[0092] A similar result regarding the proportion of days with bloody diarrhea was obtained. The value was significantly higher in the control group as compared with vaccinated group with the universal vaccine ($\text{Chi}^2 = 7.25$; $p = 0.007$) and autovaccinated group ($\text{Chi}^2 = 16.6$; $p < 0.001$).

[0093] In addition, the bloody diarrhoea began earlier in the control group (two days post challenge). In this group all pigs had bloody diarrhoea on day 6 post-challenge and for 5 days the bloody diarrhoea affected more than 50% of pigs (Figure 7).

[0094] No statistically significant differences were found between vaccinated with the universal vaccine and autovaccinated pigs in the proportion of days with diarrhoea ($\text{Chi}^2 = 0.57$; $p = 0.45$) nor with bloody diarrhoea ($\text{Chi}^2 = 1.92$; $p = 0.165$).

4. - Average daily gain

	Average daily gain at 9 days post-challenge	
	ADG (kg)	Standard deviation
Group 1 (Universal vaccine)	0.05	0.249
Group 2 (Autovaccine)	0.27	0.372
Group 3 (Control)	-0.29	0.308

[0095] In the first 9 days after challenge, almost no weight gain was observed in pigs from the vaccinated with the universal vaccine group and a mean daily gain of 0.27 kg was determined in animals from the autovaccinated group. However, no significant differences were demonstrated when comparing both groups. These groups showed no weight loss at any time during the whole trial.

	Average daily gain at 24 days post-challenge	
	ADG (kg)	Standard deviation
Group 1 (Universal vaccine)	0.24	0.263
Group 2 (Autovaccine)	0.13	0.212
Group 3 (Control)	0.20	0.185

[0096] Animals from the control group showed a clear loss of weight during the first 9 days after challenge. The average weight loss was 0.29 kg/day. After these 9 days, significant differences were not found in the average daily gain (ADG) of survivor pigs of the control group compared with that of pigs of vaccinated with the universal vaccine and autovaccinated groups (Figures 8 and 9).

[0097] Animals from the autovaccinated group showed the lower average daily gain when analyzing at 24 days post challenge, probably as a consequence of the longer incubation period of the disease in these animals. On the other hand, animals from the vaccinated with the universal vaccine and control groups showed a clear recovery of daily weight gain at this moment since they were affected previously by clinical disease.

Conclusions

[0098] The objective of the study was to compare the effectiveness of a universal vaccine (in this case composed by three selected strains, none of which was the strain causing the infection) with that of an autovaccine in very stringent conditions.

- The infection of pigs with B204 strain using three daily doses of 10^9 bacteria and inducing a high dysbiosis in the intestine causes severe swine dysentery and a mortality of 50 % of untreated pigs in the control group.
- There are no differences in the effectiveness of the universal vaccine and the autovaccine in the reduction of mortality caused by swine dysentery.
- There are not statistically significant differences in the effectiveness of the universal vaccine and the autovaccine in the reduction of clinical signs of swine dysentery (diarrhoea and bloody diarrhoea).
- There was no weight loss in pigs vaccinated with the universal vaccine neither in those vaccinated with the autovaccine.

[0099] The effectiveness of the universal vaccine is comparable with the effectiveness of an effective autovaccine. The universal vaccine has a good cost/benefit relationship for the control of swine dysentery in field conditions, considering the tested effectiveness of the autovaccines.

Example 6. Lipopolysaccharide (LPS) ELISA study of hiperimmunized rabbits

[0100] The aim of the following study was to show the qualitative differences found between the serological immune response of each of the three strains (A, B and C, see below for the exact reference) contained in the trivalent *Brachyspira hyodysenteriae* vaccine formula (universal vaccine).

Material and methods

[0101] For the experiment, nine rabbits were separated in three groups of three animals and each group was intravenous inoculated with one of the strains during six days (D1, D2, D3, D4, D5 and D10 of the study) with 0, 5 mL of the bacterial suspension. Thus, for each bacteria was necessary the preparation of 0,5 ml x 3 animals per strain x 6 days = 9 ml of 10^{10} bacteria/mL culture.

[0102] The inoculum was prepared from a pure liquid culture of each strain in 100 ml BHI (Brain Heart Infusion) with 6% BFS (Bovine Fetal Serum). Liquid culture was centrifuged and washed three times with PBS Buffer; initial suspension (growth to 10^9 bacteria/mL aprox.) was concentrated ten times to a final suspension 10^{10} bacteria/mL.

[0103] Blood was collected days D15, D18, D21, D24, D27 and D36 from each animal. Sera were sent immediately to Aquilón facilities for antibody analysis.

[0104] ELISA plates were coated separately with 0,5 μ g LPS antigen of each strain, obtained as described in Hassan et al. (Antibody response to experimental *Salmonella typhimurium* infection in chickens measured by ELISA (1990). Vet rec. 126(21):519-22) and ELISA was performed following the method for *Salmonella* described by Collazos (Aportaciones al diagnóstico y control de la salmonelosis porcina (2008). Tesis Doctoral. Universidad de Leon).

ELISA designation	Laboratory ID	Deposit code
A	H57	CNCM I - 4720
B	H170	CNCM I - 4721
C	H219	CNCM I - 4722

[0105] Results The results can be seen on figures 10, 11 and 12. Differences between ELISA plates coated with LPS coming from the three spirochaete strains against sera of a group of rabbits hiperimmunized with these three strains separately can be observed. It has been demonstrated that the sera immune response produced by each of the spirochaete strain here used (A, B and C) is different depending on whether the LPS coating of the ELISA plate is homologous or heterologous to the sera strain (see figures 10, 11 and 12). These results confirm the fact that genetically separated strains show a specific antibody production. Accordingly, the inventors have been able to surprisingly detect differences

in the immune response/animal's antibody production due to immunization with the bacteria that were selected on the basis of their genetic diversity, as described in the application, and this genetic diversity criteria is not functional sequence-driven. These unexpected results justify the inclusion of several antigenic patterns in the vaccine formula, especially taking into account that the genetic criteria used is not "gene-driven", but just based in genomic polymorphism.

SEQUENCE LISTING

[0106]

<110> Aquilón CYL, S.L.

<120> Swine dysentery vaccine

<130> 164457

<150> EP13382255

<151> 2013-06-28

<160> 16

<170> PatentIn version 3.5

<210> 1

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer sequence Bhyo_6 F

<400> 1

aaatataact catattcata acaag 25

<210> 2

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer sequence Bhyo_6 R

<400> 2

agagaacttc aaaaaacttc 20

<210> 3

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer sequence Bhyo_7 F

<400> 3

agtaataaat taaaaaatct ctagggtgg 29

<210> 4

<211> 20

<212> DNA

<213> Artificial Sequence
 <220>
 <223> Primer sequence Bhyo_7 R
 5
 <400> 4
 ggtttgtag aacaatctgc 20
 <210> 5
 10 <211> 23
 <212> DNA
 <213> Artificial Sequence
 <220>
 15 <223> Primer sequence Bhyo_12 F
 <400> 5
 cgtatgatta tttactgt cag 23
 20 <210> 6
 <211> 22
 <212> DNA
 <213> Artificial Sequence
 25 <220>
 <223> Primer sequence Bhyo_12 R
 <400> 6
 30 tttattaca gcaactttac tc 22
 <210> 7
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 35 <220>
 <223> Primer sequence Bhyo_17 F
 <400> 7
 40 ttttgccat aaatatctct c 21
 <210> 8
 <211> 19
 <212> DNA
 45 <213> Artificial Sequence
 <220>
 <223> Primer sequence Bhyo_17 R
 50 <400> 8
 gaaatgccgt ccttcttag 19
 <210> 9
 55 <211> 24
 <212> DNA
 <213> Artificial Sequence
 <220>

<223> Primer sequence Bhyo_21 F
 <400> 9
 5 aaaataatga tgaagtatct aatg 24
 <210> 10
 <211> 22
 <212> DNA
 <213> Artificial Sequence
 10
 <220>
 <223> Primer sequence Bhyo_21 R
 <400> 10
 15 aagtatcagg taaaggtaaa tc 22
 <210> 11
 <211> 19
 <212> DNA
 20 <213> Artificial Sequence
 <220>
 <223> Primer sequence Bhyo_22 F
 25 <400> 11
 agattaaaaa ctgacggag 19
 <210> 12
 <211> 19
 30 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Primer sequence Bhyo_22 R
 35 <400> 12
 agcacaagaa ccttcaaac 19
 <210> 13
 40 <211> 28
 <212> DNA
 <213> Artificial Sequence
 <220>
 45 <223> Primer sequence Bhyo_10 F
 <400> 13
 ctctctttta tatttttat tatagtg 28
 50 <210> 14
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 55 <220>
 <223> Primer sequence Bhyo_10 R
 <400> 14

ttgatgaaat tagaccattc 20

<210> 15

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer sequence Bhyo_23 F

<400> 15

cacccttag acttattatt ttatttg 28

<210> 16

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer sequence Bhyo_23 R

<400> 16

ttgttctgcg tgcgtgtag 19

Claims

1. A composition comprising bacteria from at least three genetically diverse strains of *Brachyspira hyodysenteriae*, wherein at least one of the strains is the strain with deposit number CNCM I-4720, at least one of the strains is the strain with deposit number CNCM I-4721 and at least one of the strains is the strain with deposit number CNCM I-4722.
2. The composition according to claim 1, wherein the bacteria are inactivated.
3. The composition according to claims 1 and/or 2, wherein the bacteria are present in a concentration of between 10^8 and 10^9 of total bacteria/mL.
4. The composition according to one or more of the preceding claims further comprising an adjuvant selected from the group consisting of aluminum salts and mineral oils
5. The composition according to claim 4, wherein the adjuvant is an oil adjuvant.
6. A composition according to one or more of the preceding claims for use as a vaccine against swine dysentery, wherein the swine dysentery is caused by *Brachyspira hyodysenteriae*.
7. The composition for use according to claim 6, wherein the genetically diverse strains of the composition are detected in a proportion of at least 1 % with respect to the total of detected strains in a region of interest.
8. The composition for use according to claim 7, wherein the region of interest is Spain.
9. The composition for use according to one or more of claims 6-8, wherein the vaccine is administered by parenteral administration.
10. The composition for use according to one or more of claims 6 to 9, wherein the swine are vaccinated two weeks after weaning.
11. The composition for use according to claim 10, wherein the swine are revaccinated two weeks after the first vaccination.

12. The composition for use according to one or more of claims 6 to 11, wherein the total number of bacteria per dose administrated to swine is between 10^8 and 10^9 bacteria.

13. A bacteria strain deposited at the *Collection Nationale de Cultures de Microorganismes* (CNCM), Institut Pasteur with registration number CNCM I-4720.

Patentansprüche

1. Zusammensetzung, umfassend Bakterien von wenigstens drei genetisch diversen Stämmen von *Brachyspira hyodysenteriae*, wobei wenigstens einer der Stämme der Stamm mit der Hinterlegungsnummer CNCM I-4720 ist, wenigstens einer der Stämme der Stamm mit der Hinterlegungsnummer CNCM I-4721 ist und wenigstens einer der Stämme der Stamm mit der Hinterlegungsnummer CNCM I-4722 ist.

2. Zusammensetzung gemäß Anspruch 1, wobei die Bakterien inaktiviert sind.

3. Zusammensetzung gemäß den Ansprüchen 1 und/oder 2, wobei die Bakterien in einer Konzentration von zwischen 10^8 und 10^9 Gesamt-Bakterien/ml vorliegen.

4. Zusammensetzung gemäß einem oder mehreren der vorstehenden Ansprüche, welche weiterhin ein Adjuvans umfasst, ausgewählt aus der Gruppe, bestehend aus Aluminiumsalzen und Mineralölen.

5. Zusammensetzung gemäß Anspruch 4, wobei das Adjuvans ein Öl-Adjuvans ist.

6. Zusammensetzung gemäß einem oder mehreren der vorstehenden Ansprüche zur Verwendung als Impfstoff gegen Schweinedysenterie, wobei die Schweinedysenterie durch *Brachyspira hyodysenteriae* verursacht wird.

7. Zusammensetzung zur Verwendung gemäß Anspruch 6, wobei die genetisch diversen Stämme der Zusammensetzung in einem Anteil von wenigstens 1% in Bezug auf die Gesamtzahl detektierter Stämme in einer interessierenden Region detektiert werden.

8. Zusammensetzung zur Verwendung gemäß Anspruch 7, wobei die interessierende Region Spanien ist.

9. Zusammensetzung zur Verwendung gemäß einem oder mehreren der Ansprüche 6-8, wobei der Impfstoff durch parenterale Verabreichung verabreicht wird.

10. Zusammensetzung zur Verwendung gemäß einem oder mehreren der Ansprüche 6 bis 9, wobei die Schweine zwei Wochen nach Entwöhnung geimpft werden.

11. Zusammensetzung zur Verwendung gemäß Anspruch 10, wobei die Schweine zwei Wochen nach der ersten Impfung erneut geimpft werden.

12. Zusammensetzung zur Verwendung gemäß einem oder mehreren der Ansprüche 6 bis 11, wobei die Gesamtzahl an Bakterien pro Schweinen verabreichter Dosis zwischen 10^8 und 10^9 Bakterien beträgt.

13. Bakterienstamm, hinterlegt bei der *Collection Nationale de Cultures de Microorganismes* (CNCM), Institut Pasteur, mit der Registrierungsnummer CNCM I-4720.

Revendications

1. Composition comprenant des bactéries provenant d'au moins trois souches génétiquement différentes de *Brachyspira hyodysenteriae*, dans laquelle au moins l'une des souches est la souche portant le numéro de dépôt CNCM I-4720, au moins l'une des souches est la souche portant le numéro de dépôt CNCM I-4721 et au moins l'une des souches est la souche portant le numéro de dépôt CNCM I-4722.

2. Composition selon la revendication 1, dans laquelle les bactéries sont inactivées.

EP 3 013 363 B9

3. Composition selon les revendications 1 et/ou 2, dans laquelle les bactéries sont présentes en une concentration comprise entre 10^8 et 10^9 de bactéries totales/mL.
4. Composition selon une ou plusieurs des revendications précédentes, comprenant en outre un adjuvant sélectionné parmi le groupe constitué de sels d'aluminium et d'huiles minérales.
5. Composition selon la revendication 4, dans laquelle l'adjuvant est un adjuvant huileux.
6. Composition selon une ou plusieurs des revendications précédentes pour une utilisation en tant que vaccin contre la dysenterie porcine, dans laquelle la dysenterie porcine est causée par *Brachyspira hyodysenteriae*.
7. Composition pour une utilisation selon la revendication 6, dans laquelle les souches génétiquement différentes de la composition sont détectées en une proportion d'au moins 1 % par rapport au total des souches détectées dans une région d'intérêt.
8. Composition pour une utilisation selon la revendication 7, dans laquelle la région d'intérêt est l'Espagne.
9. Composition pour une utilisation selon une ou plusieurs des revendications 6 à 8, dans laquelle le vaccin est administré par administration parentérale.
10. Composition pour une utilisation selon une ou plusieurs des revendications 6 à 9, dans laquelle les porcs sont vaccinés deux semaines après le sevrage.
11. Composition pour une utilisation selon la revendication 10, dans laquelle les porcs sont de nouveau vaccinés deux semaines après la première vaccination.
12. Composition pour une utilisation selon une ou plusieurs des revendications 6 à 11, dans laquelle le nombre total de bactéries par dose administrée aux porcs est compris entre 10^8 et 10^9 bactéries.
13. Souche bactérienne déposée auprès de la *Collection nationale de cultures de microorganismes* (CNCM), Institut Pasteur, portant le numéro d'enregistrement CNCM I-4720.

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6





Figure 7

A)



B)




Figure 8




Figure 9




Figure 10




Figure 11





Figure 12



REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 4748019 A [0010]
- US 5750118 A [0010]
- US 5281416 A [0010]
- EP 13382255 A [0106]

Non-patent literature cited in the description

- HIDALGO, A. et al. *Journal of clinical microbiology*, 2010, vol. 48 (8), 2859-2865 [0002]
- ALVAREZ-ORDÓÑEZ, A. et al. *International Journal of Environmental Research and Public Health*, 2013, vol. 10, 1927-1947 [0003] [0006] [0008] [0009]
- HIDALGO, A. et al. *Journal of Clinical Microbiology*, 2010, vol. 48 (8), 2859-2865 [0004] [0021] [0034]
- DIEGO, R. et al. *Vaccine*, 1995, vol. 13 (7), 663-667 [0007] [0034]
- JOENS, L.A. et al. *American Journal of Veterinary Research*, 1979, vol. 40, 1352-1354 [0008]
- HUDSON, M.J. et al. *British Veterinary Journal*, 1974, vol. 130, 37-40 [0008]
- HUDSON, M.J. et al. *Research in Veterinary Science*, 1976, vol. 21, 366-367 [0008]
- GLOCK, R.D. et al. *Proceedings of the 6th International Pig Veterinary Society Congress*, 1980, 521 [0008]
- GABE et al. *Infection and Immunity*, 1995, vol. 63, 142-148 [0009]
- LA, T. et al. *Veterinary Microbiology*, 2004, vol. 102, 97-109 [0009] [0010] [0034] [0056]
- HOLDEN, J. et al. *Veterinary Microbiology*, 2008, vol. 128, 354-363 [0009]
- WATERS, W.R. et al. *Vaccine*, 2000, vol. 18, 711-719 [0010]
- HAMPSON, D.J. et al. *Diseases of Swine*. Blackwell Publishing Professional, 2006, 687-688 [0010]
- GRUNDMANN, H. et al. *Journal of Clinical Microbiology*, 2001, vol. 39, 4190-4192 [0018]
- BAUM, D.H. et al. *Infection and immunity*, 1979, vol. 25, 792-796 [0019]
- HAMPSON, D.J. et al. *Epidemiology and Infection*, 1989, vol. 102, 75-84 [0019]
- HAMPSON, D.J. et al. *Epidemiology and Infection*, 1990, vol. 105, 79-85 [0019]
- Swine dysentery. HAMPSON, D.J. et al. *Intestinal Spirochaetes in Domestic Animals and Humans*. CAB International, 1997, 175-209 [0019]
- HARRIS et al. *Swine Dysentery* [0020]
- Disease of Swine. Iowa State University Press, 1999, 579-600 [0020]
- HIDALGO, Á. et al. *Epidemiology & Infection*, 2010, vol. 138, 76-85 [0061]
- HUNTER, P. R. ; M. A. GASTON. *Journal of Clinical Microbiology*, 1988, vol. 26, 2465-2466 [0066]
- GRUNDMANN et al. *Journal of Clinical Microbiology*, 2001, vol. 39, 4190-4192 [0066]
- FEIL, E. J. et al. *Journal of Bacteriology*, 2004, vol. 186, 1518-1530 [0066]
- SMITH et al. *Proceedings of the National Academy of Sciences U. S. A.*, 1993, vol. 90, 4384-4388 [0066]
- HAUBOLD et al. *Genetics*, 1998, vol. 150, 1341-1348 [0066]
- HASSAN et al. Antibody response to experimental *Salmonella typhimurium* infection in chickens measured by ELISA. *Vet rec.*, 1990, vol. 126 (21), 519-22 [0104]